Press release
KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology
– Sebetralstat pharmacokinetic and pharmacodynamic data support globalization of the KONFIDENT phase 3 clinical trial and use in short-term prophylaxis – –
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Sebetralstat pharmacokinetic and pharmacodynamic data support globalization of the KONFIDENT phase 3 clinical trial and use in short-term prophylaxis –\n\n\n– Real-world patient data show significant burden from HAE still remains on patients receiving modern long-term prophylaxis and challenges associated with treatment decisions –\n\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented data on sebetralstat and quality of life issues experienced by people living with hereditary angioedema (HAE) at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Hamburg, Germany.\n\n\nThe following presentations occurred at EAACI 2023:\n\n\n\nResults From a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial Evaluating Sebetralstat Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability in Healthy Japanese, Chinese, and White Adults: Michihiro Hide, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan (Flash Talk)\n\n\n\nShort-Term Prophylaxis with Sebetralstat, an Investigational Oral On-Demand Treatment for Hereditary Angioedema, in KONFIDENT-S: Jonathan A. Bernstein, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, LLC, Cincinnati, OH, US (Poster Presentation)\n\n\n\nRemaining burden of hereditary angioedema (HAE) attacks despite modern long-term prophylaxis: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON Canada (Flash Talk)\n\n\n\nUnderstanding the complex decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks: Anete Grumach, Centro Universitário Faculdade de Medicina do ABC (FMABC), Santo André, Brazil (Poster Presentation)\n\n\n\nPatients delay treating hereditary angioedema (HAE) attacks with currently available, injectable, on-demand therapies: associated with on-demand treatment of hereditary angioedema (HAE) attacks: Anna Valerieva, Medical University of Sofia, Sofia, Bulgaria (Poster Presentation, also selected for the EAACI Junior Member Poster Session)\n\n\n\nThe first presentation ...